ABOS
Price
$3.16
Change
-$0.03 (-0.94%)
Updated
Aug 21 closing price
Capitalization
228.52M
85 days until earnings call
Intraday BUY SELL Signals
CELC
Price
$93.53
Change
+$2.96 (+3.27%)
Updated
Aug 21 closing price
Capitalization
4.58B
87 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABOS vs CELC

ABOS vs CELC Comparison Chart in %
View a ticker or compare two or three
VS
ABOS vs. CELC commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABOS is a Hold and CELC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 23, 2026
Stock price -- (ABOS: $3.16 vs. CELC: $93.53)
Brand notoriety: ABOS and CELC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABOS: 119% vs. CELC: 49%
Market capitalization -- ABOS: $228.52M vs. CELC: $4.58B
ABOS [@Biotechnology] is valued at $228.52M. CELC’s [@Biotechnology] market capitalization is $4.58B. The market cap for tickers in the [@Biotechnology] industry ranges from $138.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABOS’s FA Score shows that 0 FA rating(s) are green whileCELC’s FA Score has 0 green FA rating(s).

  • ABOS’s FA Score: 0 green, 5 red.
  • CELC’s FA Score: 0 green, 5 red.
According to our system of comparison, both ABOS and CELC are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABOS’s TA Score shows that 7 TA indicator(s) are bullish while CELC’s TA Score has 3 bullish TA indicator(s).

  • ABOS’s TA Score: 7 bullish, 4 bearish.
  • CELC’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, ABOS is a better buy in the short-term than CELC.

Price Growth

ABOS (@Biotechnology) experienced а +18.35% price change this week, while CELC (@Biotechnology) price change was +1.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +15.94%, and the average quarterly price growth was +3349.70%.

Reported Earning Dates

ABOS is expected to report earnings on Nov 16, 2026.

CELC is expected to report earnings on Nov 18, 2026.

Industries' Descriptions

@Biotechnology (+3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CELC($4.58B) has a higher market cap than ABOS($229M). ABOS YTD gains are higher at: 49.763 vs. CELC (-6.226). ABOS has higher annual earnings (EBITDA): -108.82M vs. CELC (-172.66M). CELC has more cash in the bank: 387M vs. ABOS (128M). ABOS has less debt than CELC: ABOS (31.2M) vs CELC (323M). ABOS (0) and CELC (0) have equivalent revenues.
ABOSCELCABOS / CELC
Capitalization229M4.58B5%
EBITDA-108.82M-172.66M63%
Gain YTD49.763-6.226-799%
P/E RatioN/AN/A-
Revenue00-
Total Cash128M387M33%
Total Debt31.2M323M10%
FUNDAMENTALS RATINGS
CELC: Fundamental Ratings
CELC
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
PROFIT vs RISK RATING
1..100
43
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
52
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABOSCELC
RSI
ODDS (%)
Bearish Trend 3 days ago
89%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
83%
Momentum
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 6 days ago
83%
Declines
ODDS (%)
Bearish Trend about 1 month ago
87%
Bearish Trend 13 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
89%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
ABOS
Daily Signal:
Gain/Loss:
CELC
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SMUP5.070.33
+6.96%
T-REX 2X Long SMR Daily Target ETF
VONE347.101.40
+0.40%
Vanguard Russell 1000 ETF
FRI32.06N/A
-0.01%
First Trust S&P REIT ETF
DFCA49.44-0.09
-0.18%
Dimensional California Municipal Bd ETF
LABX10.52-0.42
-3.84%
Tradr 2X Long ALAB Daily ETF

ABOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABOS has been loosely correlated with CCXI. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ABOS jumps, then CCXI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABOS
1D Price
Change %
ABOS100%
-0.94%
CCXI - ABOS
48%
Loosely correlated
+3.55%
CELC - ABOS
44%
Loosely correlated
+3.27%
NKTX - ABOS
42%
Loosely correlated
+7.69%
EDIT - ABOS
40%
Loosely correlated
+5.78%
RCKT - ABOS
40%
Loosely correlated
+0.86%
More

CELC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELC has been closely correlated with IMA. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if CELC jumps, then IMA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELC
1D Price
Change %
CELC100%
+3.27%
IMA - CELC
76%
Closely correlated
-3.16%
SLXN - CELC
50%
Loosely correlated
-1.23%
ABOS - CELC
44%
Loosely correlated
-0.94%
ANRO - CELC
39%
Loosely correlated
+0.09%
GLSI - CELC
39%
Loosely correlated
+8.88%
More